N/A N=68 Mild Cognitive Impairment and Obstructive Sleep Apnea
Obstructive Sleep Apnea · Mild Cognitive Impairment
Primary: Hopkins Verbal Learning Test-Revised (HVLT-R) — 23.52; 20.04; 23.68; 20.39 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=250 Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography
Breast Cancer · Tumors, Breast · Cancer Screening
Primary: Number of Participants With Imaging Data Collected — 249; 1 Participants
Phase 3 N=4,884 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
Breast Cancer
Primary: Disease-free Survival (DFS) — 87.5; 85.8 percentage of patients — p=.31
N/A N=46 Individually Tailored Lighting System to Improve Sleep in Older Adults
Sleep Disturbances
Primary: Sleep Disturbance — -1.9; -1.3 units on a scale
Phase 4 N=130 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing
Prophylaxis of Acute Mountain Sickness
Primary: Number of Participants With Acute Mountain Sickness as Measured by the Lake Louise Score — 21; 21 Participants
Phase 2 N=20 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Metastatic Leiomyosarcoma
Primary: Response Rate (Per RECIST 1.1) — 1 Participants
Phase 3 N=42 Growth Hormone Therapy in Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
N/A N=84 A Study of the Effectiveness and Efficacy of the PowerSleep Device
Sleep Deprivation · Insufficient Sleep Syndrome · Healthy
Primary: Average Amount of Slow Wave Activity Delivered by the Powersleep Device With and Without Stimulation — 1649.41; 1643.84 microvolts^2 — p=0.363
Phase 2 N=10 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Aggressive Systemic Mastocytosis · Mast Cell Leukemia · Systemic Mastocytosis
Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants
N/A N=20 rTMS in First Episode Psychosis
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder
Primary: Cognitive Performance — 2.22; -0.50; 6.11; -3.70 BACS Composite Score
N/A N=44 Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device
Sleep Disordered Breathing · Sleep Apnea, Central
Primary: Apnea Hypopnea Index — 10.44; 6.06 events/hour — p=0.0054
Phase 3 N=1,686 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Migraine, With or Without Aura
Primary: Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose — 14.3; 20.7; 21.8 percentage of participants — p=0.0285
N/A N=14 Measuring Head Control Change With 2D Video Analysis After Utilization of Headpod in Children With Poor Head Control
To Determine Efficacy of the Headpod · Cerebral Palsy
Primary: Change in Head Holding Active Time From Baseline to 6 Months — 83.63 Seconds
Phase 2 N=140 Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis (NASH)
Primary: Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 89.3; 76.8; 67.9; 1.8 Percentage of…
N/A N=100 EDWARDS INTUITY Valve System CADENCE-MIS Study
Aortic Valve Disease · Aortic Stenosis
Primary: Median Subject Time Spent on Cardiopulmonary Cross Clamp — 35.0; 47.5 Minutes — p=<0.0001